Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorukafusp alfa - Apeiron Biologics

Drug Profile

Lorukafusp alfa - Apeiron Biologics

Alternative Names: Anti-ganglioside-GD2-antibody-interleukin-2-fusion-protein; APN 301; ch14.18-IL2; EMD 273063; hu14.18-IL2

Latest Information Update: 30 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lexigen Pharmaceuticals
  • Developer Apeiron Biologics; Merck KGaA; National Cancer Institute (USA); University of Wisconsin-Madison
  • Class Antineoplastics; Immunoglobulin fusion proteins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma; Neuroblastoma

Most Recent Events

  • 14 Aug 2019 Phase I/II clinical trials in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (Intratumoural) (NCT03958383)
  • 27 May 2019 University of Wisconsin in collaboration with National Cancer Institute, Bristol-Myers Squibb, Apeiron Biologics, and Provenance Biopharmaceuticals plans a phase I/II trial in Malignant melanoma (Inoperable/Unresectable, Combination therapy, Late stage disease) in USA in July 2019 (NCT03958383)
  • 11 Jul 2017 The University of Wisconsin plans a phase I trial for Neuroblastoma (In combination with natural killer cells, In infants, In children, In adolescents, In adults) in USA in September 2017 (NCT03209869)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top